SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, ...
SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, ...
Quidel plans initial release to professional and point-of-care segments with a goal of expansion to serve telemedicine and home markets Sofia Q is the latest product in Quidel’s best-selling Sofia ...
QuidelOrtho Corporation QDEL recently announced that it has been granted a CLIA Waiver by the FDA, which applies to its new Sofia 2 SARS Antigen+ FIA (fluorescent immunoassay). The Sofia 2 SARS ...
Since the start of the pandemic, the FDA has issued emergency use authorizations to a whopping 444 diagnostic tests and sample collection devices to detect the COVID-19 virus. In recent months, ...
After issuing an emergency use authorization (EUA) for the first antigen test for coronavirus disease (COVID-19) over the weekend, the US Food and Drug Administration (FDA) on Monday updated its EUA ...
Last week, QuidelOrtho Corporation QDEL announced the availability of QUICKVUE Influenza + SARS Test. The CLIA-waived, 510(k)–cleared rapid, easy-to-use immunoassay is the latest addition to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results